Prophylaxis and Treatment of NSAID-Induced Gastroduodenal Disorders

@article{Corte1999ProphylaxisAT,
  title={Prophylaxis and Treatment of NSAID-Induced Gastroduodenal Disorders},
  author={Dr Renato Corte and Michele Caselli and Gabriella Castellino and Gianluigi Bajocchi and Francesco Trotta},
  journal={Drug Safety},
  year={1999},
  volume={20},
  pages={527-543}
}
A significant percentage of patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) experience some type of adverse gastrointestinal symptoms, lesions of the gastroduodenal tract being clinically the most relevant.NSAIDs cause gastrointestinal damage by 2 independent mechanisms: a topical effect, which is pH and pKa related, and a systemic effect mediated by cyclo-oxygenase (COX) inhibition with a reduction in prostaglandin synthesis. Using endoscopy, gastroduodenal lesions identified… Expand
Tolérance gastro-intestinale des anti-inflammatoires non-stéroïdiens
TLDR
The relative GI safety of nabumetone may be attributed to its lack of direct and indirect topical effects because of its nonacidic nature and absence of enterohepatic recirculation, and animal data have suggested that nabuetone has a low ulcerogenic potential in comparison with other available NSAIDs. Expand
Esomeprazole for the Management of Upper Gastrointestinal Symptoms in Patients Who Require NSAIDs
TLDR
Estateprazole proved effective for both short-term resolution of, and sustained relief from, upper GI symptoms in long-term NSAID users, and was well tolerated. Expand
Non-Steroidal Anti-Inflammatory Drugs and Gastroprotection with Proton Pump Inhibitors
TLDR
The co-prescription of proton pump inhibitors (PPIs) for the prevention of NSAID-induced gastropathy is reviewed, with a particular focus on the first fixed-dose NSAID/PPI formulation: ketoprofen/omeprazole modified-release capsules. Expand
The Use of Gastroprotectants in Treating Gastric Ulceration in Dogs
TLDR
This article reviews the various gastroprotectant medications, including their mechanisms of action, means of administration, side effects, and efficacy in various disease states. Expand
Drug utilization study of co-administration of nonsteroidal anti-inflammatory drugs and gastroprotective agents in an orthopaedics outpatients department of a tertiary care hospital in West Bengal
Non-steroidal anti-inflammatory drugs (NSAIDs) are most commonly used drugs for years for management of pain and inflammation with good efficacy and represent most widely prescribed class ofExpand
Can aprepitant used for nausea and vomiting be good gastrointestinal complaints?
TLDR
It is argued that it will not be necessary to add a new gastric protective agent as it also shows beneficial effects in gastrointestinal complaints when aprepitant is given as an anti-nausea and vomiting drug to cancer patients undergoing chemotherapy. Expand
Co-Administration of Nonsteroidal Ant-Inflammtory Drugs and Gastropotective Drugs in Orthopaedic Out Patient Department of a University Hospital in Kashmir
TLDR
The most common gastroprotective agents combined with nonsteroidal antinflammatory drugs were PPI(proton pump inhibitors)[52.46percent] followed by H2 receptor antagonists[32.73],while antacids[14.73] were prescribed least. Expand
Celecoxib versus a Non-Selective NSAID Plus Proton-Pump Inhibitor
TLDR
Evidence shows that concurrent use of a non-selective NSAID (such as naproxen) plus a PPI is as effective in preventing NSAID gastropathy as celecoxib, and may be more cost-effective. Expand
The comparative effects of oral famotidine and lansoprazole in prophylaxis of aspirin induced peptic ulcer in albino rat
TLDR
All the two drugs like famotidine, lansoprazole prevented the ulcerogenic effects of Aspirin effectively, although not completely, according to the results. Expand
Predicting the risk for gastrointestinal toxicity in patients taking NSAIDs: The Gastrointestinal Toxicity Survey
TLDR
Results obtained with GITS (NI) are highly correlated with those from SCORE and may provide physicians with information that will help them avoid administering NSAIDs to patients who are at high risk for adverse GI reactions. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 95 REFERENCES
Epidemiology and economics of NSAID-induced gastropathy.
  • H. Zeidler
  • Medicine
  • Scandinavian journal of rheumatology. Supplement
  • 1992
TLDR
Cost-benefit analyses indicate that preventing potential GI damage with agents such as misoprostol may reduce the expense of treating the GI side effects associated with NSAID therapy. Expand
Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies.
TLDR
New methods are needed for early noninvasive detection of mucosal damage by NSAIDs and for the identification of individuals who should receive prophylactic therapy against the development of ulcerations and serious complications from NSAIDs. Expand
Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs.
TLDR
Miscoprostol is the only antiulcer drug proven to be effective for preventing NSAID-induced gastric and duodenal ulcers in patients receiving chronic NSAID therapy, and no meaningful data exist with organic bismuth salts. Expand
Nonsteroidal anti-inflammatory drugs--the clinical dilemmas.
  • D. McCarthy
  • Medicine
  • Scandinavian journal of gastroenterology. Supplement
  • 1992
TLDR
Initial symptoms, poorly correlated with endoscopic findings, are relieved by anti-ulcer drugs and ameliorate with time of NSAID use in most patients, a clinical dilemma. Expand
Nonsteroidal anti-inflammatory drugs and peptic ulcer disease.
TLDR
Nonsteroidal anti-inflammatory drugs thus appear both to exacerbate an underlying peptic diathesis and to cause de novo ulcers. Expand
Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee.
  • C. Hawkey
  • Medicine
  • The American journal of medicine
  • 1998
TLDR
The data show that omeprazole is an effective and well-tolerated agent for both primary and secondary (maintenance) prophylaxis in patients receiving NSAIDs. Expand
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
TLDR
Treatment with high-dose famotidine significantly reduces the cumulative incidence of both gastric and duodenal ulcers in patients with arthritis receiving long-term NSAID therapy. Expand
Non-steroidal anti-inflammatory drugs: how do they damage the gut?
TLDR
This review will highlight the epidemiology of NSAID-induced gastrointestinal toxicity, their effects on prostaglandins, and the phenomenon of cytoprotection, as well as the effects of NSAIDs on the small intestine and colon. Expand
Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs
TLDR
This objective was to determine whether concurrent therapy with misoprostol reduces the incidence of serious upper gastrointestinal complications in older patients with chronic rheumatoid arthritis who are taking NSAIDs. Expand
Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers.
TLDR
It is shown that ranitidine 150 mg twice daily effectively heals NSAID associated peptic ulcers and Healing is more successful when NSAID treatment stops but even if these drugs are continued, substantial healing rates are achievable. Expand
...
1
2
3
4
5
...